
ECCO 2022

Read the full Report (pdf)
European Crohn's and Colitis Organisation 16-19 February 2022
Featured articles

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

CONTENTS
Online First
Novel Treatment Modalities
Guselkumab shows encouraging safety and efficacy in ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Mirikizumab efficacious for active ulcerative colitis
Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Guselkumab plus golimumab promising combination for ulcerative colitis
Combined endpoint may support personalised medicine in ulcerative colitis

Filgotinib seems promising for perianal fistulising Crohn’s disease
Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis
Upadacitinib counters extraintestinal manifestations in ulcerative colitis
Upadacitinib effector pathways unravelled
Deucravacitinib does not meet primary endpoint for ulcerative colitis
Head-to-Head Comparisons
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis
Short-Term and Long-Term Treatment Results
Ozanimod treatment shows maintained response in ulcerative colitis

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
Vedolizumab first approved therapy for chronic pouchitis

VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met
Specific Therapeutic Strategies
Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy
Segmental colectomy beneficial over total colectomy in Chrohn’s disease

Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative
Similar results for different corticosteroid tapering protocols in UC
Miscellaneous Topics
Lessons from the COVID-19 pandemic for IBD management
AI model distinguishes between histologic activity and remission in ulcerative colitis
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Vaccination tool associated with improved vaccination coverage in IBD
Comparable safety profiles of biological therapies in elderly patients with IBD
